Siddhartha Mukherjee Says India Can Lead AI Drug Discovery for Cheaper Medicines
The oncologist sees an opportunity for India to connect advances in molecular design with stronger clinical research and more affordable treatment development.
Oncologist and author Siddhartha Mukherjee has said India could play a leading role in AI drug discovery, helping accelerate the development of medicines and reduce the resources needed to bring promising treatments forward.
Speaking at the Hindustan Times Leadership Summit in New Delhi on November 14, 2026, the Manas AI co-founder argued that progress in molecular design must be matched by improvements in clinical testing and the wider development process.
His remarks put the focus on how computational advances can translate into benefits for patients, including better access to effective treatments.
How AI Drug Discovery Can Speed Up Early Research
Drug discovery begins with understanding a disease and identifying biological processes that a treatment might influence. Researchers then investigate molecules that could produce the intended effect.
AI tools can help identify potential targets, screen compounds and propose new molecular structures. Scientists can use those predictions to decide which candidates deserve laboratory testing.
At the summit, Mukherjee said some early cancer-drug research that previously took around eight years could now be compressed into approximately three to four months using his company’s approach.
That was a claim about early research work. It did not describe the complete journey from a computer-generated molecule to an approved medicine.
The practical opportunity is to improve the selection of experiments. More useful predictions could help research teams spend less time making and testing unsuitable candidates.
What Manas AI Is Building
Manas AI, headquartered in New York, was co-founded by Mukherjee, Reid Hoffman and Ujjwal Singh.
The company’s approach to AI drug discovery combines machine learning with scientific models grounded in physics and chemistry. Its stated aim is to improve the design of molecules that bind to targets involved in disease.
In January 2026, Manas announced an agreement giving it access to Schrödinger’s computational discovery platform and specialist support. The companies described plans to combine physics-based modelling with Manas’s machine-learning systems to improve prediction and research speed.
This approach connects computational suggestions with scientific constraints. A promising molecular design must have properties that can be tested experimentally and, eventually, evaluated in a biological setting.
Clinical Trials Remain Essential
AI drug discovery can generate promising candidates, but human studies are still needed to establish how a treatment performs in patients.
A simplified development pathway shows why early research is only one part of the process:
| Development stage | Main question researchers must answer |
|---|---|
| Discovery | Which target and candidate molecule justify further investigation? |
| Preclinical research | What do laboratory studies reveal about activity and potential safety concerns? |
| Clinical research | How safe and effective is the candidate in people, and at what dose? |
| Manufacturing and regulatory review | Can the product be made consistently, and does the evidence support its proposed use? |
A molecule that performs well in an experiment may face difficulties later. Decisions about development therefore depend on accumulating reliable evidence across these stages.
Faster computational work is most useful when it improves that evidence-building process.
Why India’s Scientific Talent Matters
Mukherjee identified India’s doctors and physician-scientists as a strength in taking promising treatments through clinical development.
For India, leadership in AI drug discovery would require close collaboration between researchers who design molecules, laboratories that test them and clinical teams that understand patient needs.
This creates a practical challenge for institutions and businesses: research findings must move between disciplines without losing scientific detail or accountability.
A promising result from a computational team needs a clear experimental question. Laboratory findings then need to inform the next design decision. Clinical researchers must help determine whether the proposed treatment addresses a meaningful medical need.
Building those connections could make India’s contribution extend across more of the development process.
How Lower Research Costs Could Support Affordability
The affordability case for AI drug discovery begins with using research resources more efficiently.
If a model helps scientists prioritise better candidates, a team may be able to reduce some unsuccessful experiments and shorten particular research cycles. That could make more projects feasible within a given research budget.
However, the price patients eventually pay also reflects later development, manufacturing, distribution and commercial decisions. Savings in an early research programme do not establish what a future medicine will cost.
The opportunity is therefore to connect research efficiency with a deliberate approach to access. Developers would need to consider how a treatment can be produced, supplied and delivered alongside its scientific performance.
Reliable Data and Clear Evaluation Standards
Reliable data are central to AI drug discovery. Researchers need to understand what information a model learned from, the task it is intended to perform and how its predictions are checked.
The US Food and Drug Administration and European Medicines Agency have published shared principles for AI use in drug development. These emphasise defined uses, multidisciplinary expertise, data governance, appropriate performance assessment and clear communication.
For research teams, the implication is practical: a model should be evaluated against the decision it is supposed to support. Strong performance on one dataset or task does not automatically establish its usefulness in another setting.
India’s Wider Push for Health AI
India has also introduced broader initiatives for responsible AI in healthcare.
On February 17, 2026, the Union Health Ministry launched SAHI, the Strategy for Artificial Intelligence in Healthcare for India, and BODH, the Benchmarking Open Data Platform for Health AI.
SAHI sets out a framework for responsible adoption. BODH is designed to support systematic testing of health AI models using diverse, anonymised datasets.
These initiatives provide wider policy context for AI drug discovery, particularly around evaluation, collaboration and trust. Their relevance lies in building dependable methods for assessing technology before it is used at scale.
Turning Research Progress Into Patient Benefit
The long-term test for AI drug discovery is whether better computational methods lead to treatments that demonstrate meaningful benefits and become accessible to patients.
Useful measures of progress include reproducible laboratory findings, candidates advancing through clinical studies, dependable manufacturing and evidence of improved treatment outcomes.
India’s opportunity lies in connecting these stages. Scientific talent and increasingly capable AI systems can contribute to that work, while clinical evidence will determine which promising ideas become useful medicines.
For more insights navigate: PressPire | Stories That Shape the Future
Read previous article here : indian-ai-startups-indiaai-second-cohort/
Follow PressPire on Facebook | Instagram | LinkedIn | YouTube
PressPire | Stories That Shape the Future